<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3467">
  <stage>Registered</stage>
  <submitdate>23/02/2012</submitdate>
  <approvaldate>23/02/2012</approvaldate>
  <nctid>NCT01540539</nctid>
  <trial_identification>
    <studytitle>Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>R1154-HV-1116</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - REGN1154 or placebo

Experimental: Dosing cohort 1 - 

Experimental: Dosing cohort 2 - 

Experimental: Dosing cohort 3 - 

Experimental: Dosing cohort 4 - 

Experimental: Dosing cohort 5 - 

Experimental: Dosing cohort 6 - 

Experimental: Dosing cohort 7 - 

Experimental: Dosing cohort 8 - 


Treatment: drugs: REGN1154 or placebo
Participants will receive active drug or placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total number and severity of TEAEs - TEAEs (Treatment-emergent adverse events)</outcome>
      <timepoint>Day 1 through Day 113</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum concentration - Serum concentrations of REGN1154 over time</outcome>
      <timepoint>Day 1 through Day 113</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence or absence of antibodies - Presence or absence of antibodies against REGN1154 over time.</outcome>
      <timepoint>Day 1 through Day 113</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Healthy men and women between the ages of 18 and 65; women must be postmenopausal or
             surgically sterile

          2. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive

          3. Willing, committed, and able to return for ALL clinic visits and complete all
             study-related procedures

          4. Able to read or to understand the consent process, and willing to sign the informed
             consent form (ICF)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria include, but are not limited to the following:

          1. Any illness or condition that would adversely affect the subject's participation in
             this study

          2. Any clinically significant abnormalities observed during the screening visit

          3. Use of certain medications taken before the screening visit

          4. Onset of a new exercise routine or major change to a previous exercise routine within
             4 weeks prior to screening visit

          5. Hospitalization within 60 days of the screening visit

          6. Any condition that would place the subject at risk, interfere with participation in
             the study

          7. History of or positive human immunodeficiency virus (HIV) screen result at the
             screening visit

          8. History of certain other conditions

          9. Positive urine, drug or alcohol screen result at screening

         10. Known sensitivity to any of the components of the investigational product formulation

         11. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the
             investigational drug prior to the screening visit

         12. Live/attenuated vaccinations within 12 weeks of screening or during the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>44</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Regeneron Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to study the safety and tolerability of intravenous (IV) and
      subcutaneous (SC) administration of REGN1154 in normal healthy subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01540539</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trial Management</name>
      <address>Regeneron Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>